Teledyne to Buy Varex Imaging for $1.1B at 88% Premium

Teledyne Technologies agrees to acquire Varex Imaging at $18.90 per share—an 88% premium—securing control of photon-counting CT detector technology in a $1.1 billion all-cash deal.

Teledyne will pay $18.90 per share in cash for Varex Imaging, an 88% premium over where shares traded in late May 2026.
VREX surged nearly 48% in premarket trading Monday, rising from a Friday close of $12.41 to approximately $18.40.
Varex is among the world's only commercially ready independent suppliers of next-generation photon-counting CT detectors.

Lead

Teledyne Technologies agreed on August 10, 2026 to acquire Varex Imaging Corporation in an all-cash transaction valued at approximately $1.1 billion, offering $18.90 per share — an 88% premium over the level at which Varex shares changed hands as recently as late May. The deal hands Teledyne control of one of the world's only commercial-scale suppliers of photon-counting computed tomography detectors, the imaging architecture widely expected to displace conventional CT detector arrays as the clinical standard for the next decade.

What Happened

Under the terms of the definitive agreement, Teledyne will acquire all outstanding common shares of Varex at $18.90 in cash. The aggregate transaction value of roughly $1.1 billion accounts for Varex's equity awards and net debt as of April 3, 2026. Both companies' boards of directors unanimously approved the transaction, which is targeted to close in early 2027, subject to regulatory clearances and Varex shareholder approval.

Varex shares closed at $12.41 on Friday. In premarket trading Monday, VREX surged to approximately $18.40, a gain of roughly 48%. The discount to the $18.90 offer price reflects standard merger-arbitrage positioning ahead of approvals expected over the coming months.

Strategic Context

Teledyne and Varex serve overlapping customer bases in medical and industrial imaging, but with notably distinct product lines. Teledyne manufactures X-ray detectors across a range of applications; however, its portfolio excludes detectors suited for high-radiation environments such as oncology, and it has never produced X-ray tubes for radiography, fluoroscopy, or computed tomography. Varex fills both gaps — supplying CT-grade X-ray tubes and, critically, a new generation of photon-counting CT detectors that represent the emerging frontier of diagnostic imaging hardware.

Photon-counting CT marks a fundamental architectural shift from conventional detector technology. Rather than averaging the energy of incoming X-ray photons, photon-counting systems resolve individual photon energies, enabling sharper images, lower patient radiation doses, and the capacity to characterize specific tissue compositions — capabilities researchers and radiologists regard as transformative for clinical diagnosis.

Varex's position in this segment carries strategic weight well beyond its current revenue base. The company is among the few suppliers globally with commercially ready photon-counting detector technology at scale, a distinction that has made it an increasingly attractive acquisition target as major CT scanner manufacturers accelerate next-generation platform development.

Market Reaction

The near-48% premarket gain in VREX reflects the magnitude of the Teledyne Varex offer relative to recent trading. The $18.90 per share price implies an even steeper premium for investors who held through a period of share price weakness earlier in the year, when Varex traded near $10. The all-cash structure eliminates equity-dilution risk for TDY shareholders and reflects confidence in Teledyne's balance sheet capacity. Teledyne has an established record of acquisitions in precision instrumentation and imaging; the Varex transaction is consistent with that strategy, adding proprietary technology with minimal existing product overlap.

What Comes Next

The transaction requires approval from Varex stockholders and antitrust review in relevant jurisdictions. Teledyne and Varex indicated they do not anticipate material regulatory obstacles, citing limited competitive overlap between the two companies' current product lines. Upon closing, Varex will be integrated into Teledyne's broader imaging and electronics businesses, with its X-ray tube manufacturing and photon-counting detector capabilities adding to a portfolio positioned to serve CT scanner manufacturers through the industry's next platform transition.

Outlook

The Teledyne Varex combination arrives as the medical imaging sector undergoes a technology inflection. Adoption of photon-counting CT is accelerating, and command of a commercially proven, independent supply chain for those CT detectors carries long-term strategic value that extends beyond the $1.1 billion transaction price. With both boards aligned and regulatory friction expected to be limited, the deal is on track to close in early 2027 — at which point Teledyne will hold a pivotal supply-chain position in one of the most consequential platform transitions in diagnostic imaging in a decade.